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A hospital-based case-control 
study of identifying ovarian 
cancer using symptom index
To the editor: It used to be regarded that ovarian cancer was 
a "silent killer." However, recent studies have revealed that the 
majority of patients with ovarian carcinoma have symptoms 
for at least several months prior to their diagnosis.1-4 Dr. Kim 
and colleagues published an article in the December issue of 
Journal of Gynecologic Oncology entitled “A hospital-based 
case-control study of identifying ovarian cancer using symp-
tom index.”5 Although some data set is impressive, the title of 
the manuscript cannot either be supported or refuted by the 
analysis and may therefore be a little bit misleading.
The study included 116 women with epithelial ovarian can-
cer and 209 control women using questionnaires on eight 
symptoms. These included pelvic/abdominal pain, urinary ur-
gency/frequency, increased abdominal size/bloating, diffi-
culty eating/feeling full. The symptom index was considered 
positive if any of the 8 symptoms present for ＜1 year that oc-
curred ＞12 times per month. The symptom index was pos-
itive in 65.5% of women with ovarian cancer, in 31.1% of 
women with benign cysts, and in 6.7% of women on routine 
screening (ps＜0.001). Significantly higher proportion of 
ovarian cancer patients were positive for each symptom as 
compared with control group (ps＜0.001). Also, they con-
cluded that previous studies suggesting that specific symp-
toms were useful in identifying women with ovarian cancer.
However, the population of study is heterogeneous and 
small to represent the whole Korean population. The diag-
nosis is ovarian cancer in 116, benign ovarian cyst in 74, con-
trol group in 135 women. We also do not know the histo-
logical subtype of those ovarian cancers (i.e., epithelial, bor-
derline, or stromal). The natural course of disease and re-
sponse rate to symptoms index will be different from one his-
tological subtype to another. Likewise, some studies have 
classified the study population into three groups for compar-
ison based on their diagnosis: borderline, early and advanced 
cancer.
Finally, in future publications on this topic, it would be help-
ful to specify very carefully the population characteristics to 
classify patients with ovarian carcinoma.
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In reply: A large-scale study on the role of ovarian symptom in-
dex is necessary
We appreciate the comments by Dr. Kim YT on our study. We 
agree to his comment that the population of our study cannot 
represent the whole Korean population. A population-based 
prospective study would be necessary to determine the useful-
ness of ovarian symptom index (OSI). However, it requires 
enormous resources to perform a large-scale prospective study. 
As a preparatory step to a large-scale prospective study, our 
study was designed as a hypothesis-generating, case-control 
study. It is already well-known that OSI is associated with ovar-
ian cancer.1,2 However, we thought that the validation of OSI 
is necessary in Korean women because symptoms in English 
could be different from those in Korean.
Recently, results of large-scale, case-control study regarding 
the predictive value of OSI were published.3 Researchers con-
ducted an in-person interview with 812 women with epi-
thelial ovarian cancer or borderline tumor and 1,313 pop-
ulation-based control subjects. Although OSI was more fre-
quently positive in women with ovarian cancer than in con-
trol, the interval from symptom onset to diagnosis was short-
er than six months in over 70% women. The sensitivity and 
specificity of OSI was 68% and 95%, respectively. The esti-
mated positive predictive value of OSI based on the assumed 
prevalence of ovarian cancer was about 1%. In other words, 
only one of 100 women with positive OSI actually had an ovar-
ian cancer.
Although OSI would trigger unnecessary medical evalua-
tions in 99 of 100 women with positive OSI, the OSI still could 
play a role in screening of ovarian cancer. Specifically, the OSI 
could improve the cost-effectiveness of ovarian cancer screen-
ing programs using CA-125 and ultrasonography (USG). For 
example, in the PLCO trial, nearly 29,000 women underwent 
CA-125 and USG to detect 29 malignant ovarian, tubal or per-
itoneal tumors.4 If the OSI was examined in women partic-
ipating in PLCO trial, 20 of 29 women with malignant tumors 
would have positive OSI (68% sensitivity). In addition, to de-
tect 20 women with positive OSI and malignant tumors, only 
2,000 women should undergo CA-125 and USG (positive pre-
dictive value 1%).
In our study, all patients in ovarian cancer arm had an epi-
thelial ovarian cancer. Borderline ovarian tumor and non-epi-
thelial ovarian cancer were not included in our study. 
Although there is no definitive evidence supporting the ben-
efit of OSI, we believe that the OSI should be regularly per-
formed by the women herself like a self-breast examination 
because the OSI do not require any resources and is poten-
tially beneficial. Considering the low incidence of ovarian can-
cer, we believe that OSI could be useful in screening of ovarian 
cancer. More studies on OSI in Korean women are necessary.
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